Home Subscription Services

Quintessence International
QI Home Page
About the Editor
Editorial Board
Accepted Manuscripts
Author Guidelines
Submission Form
Reprints / Articles
Quintessence Publishing: Journals: QI
Quintessence International

Edited by Eli Eliav

ISSN 0033-6572 (print) • ISSN 1936-7163 (online)

September 2014
Volume 45 , Issue 8

Share Abstract:

Effectiveness of nano-hydroxyapatite toothpaste in reducing dentin hypersensitivity: A double-blind randomized controlled trial

Vano, Michele / Derchi, Giacomo / Barone, Antonio / Covani, Ugo

Pages: 703-711
PMID: 25019114
DOI: 10.3290/j.qi.a32240

Objective: The present double-blind randomized clinical trial aimed to compare the efficacy in reducing dentin hypersensitivity of a dentifrice formulation containing nano-hydroxyapatite with a fluoride dentifrice and a placebo.
Method and Materials: 105 subjects were recruited to participate in the study. A computer-generated random table with blocking to one of the three study treatments was used in order to have 35 subjects per group: 1) nano-hydroxyapatite 15% toothpaste, fluoride-free; 2) fluoride toothpaste; 3) placebo. Groups 1, 2, and 3 were instructed to brush their teeth for 2 minutes twice a day with the provided toothpaste. The participant’s dentin hypersensitivity was evaluated at baseline and after 2 and 4 weeks using airblast and tactile tests. In addition, a subjective evaluation using a visual analog scale (VAS) was used.
Results: Significantly lower values of cold air sensitivity and tactile sensitivity (P < .001) were found for the test group at 2 weeks and 4 weeks. In addition, statistically significantly (P < .001) lower values of sensitivity were reported for group 1 compared to groups 2 and 3, at 2 and 4 weeks respectively. The VAS scores were significantly lower (P < .001) in the test group at 2 and 4 weeks compared to baseline and to the control groups.
Conclusion: The findings of the present study encourage the application of nano-hydroxyapatite in fluoride-free toothpaste as an effective desensitizing agent providing quick relief from symptoms after 2 and 4 weeks.

Full Text PDF File | Order Article


Get Adobe Reader
Adobe Acrobat Reader is required to view PDF files. This is a free program available from the Adobe web site.
Follow the download directions on the Adobe web site to get your copy of Adobe Acrobat Reader.
  © 2020 Quintessence Publishing Co Inc

Home | Subscription Services | Books | Journals | Multimedia | Events | Blog
Terms of Use | Privacy Policy | About Us | Contact Us | Advertising | Help | Sitemap | Catalog